PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015

GAITHERSBURG, Md., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its fourth quarter and full year 2014 financial and operating results after the close of U.S. financial markets on Thursday, February 26, 2015.

In addition, management will host a conference call to discuss the quarterly and year-end financial results and provide an update on corporate activities.

Conference call details are as follows:
Date: February 26, 2015
Time: 4:30 pm US Eastern Time
Dial-in number: (877) 212-6076 (Domestic) or (707) 287–9331 (International)
Via web: www.novavax.com
Conference call replay:
Dates:  Starting at 6:31 pm ET on February 26, 2015 until midnight March 5, 2015
Dial-in number:  (855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode:  89629680
Via web:  www.novavax.com, "Investor Info"/"Events"

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, novavax.com.

CONTACT: Barclay A. Phillips
         SVP, Chief Financial Officer and Treasurer
         Andrea N. Flynn, Ph.D.
         Senior Manager, Investor Relations
         240-268-2000
         ir@novavax.com
         Novavax, Inc.David Schull or Todd Davenport, Ph.D.
         Russo Partners, LLC
         212-845-4271
         david.schull@russopartnersllc.com
         todd.davenport@russopartnersllc.com

Novavax logo

Novavax, Inc.